- |||||||||| Journal: Contraception updates for adolescents. (Pubmed Central) - Apr 2, 2025
Updated evidence-based guidelines and several new contraceptive options should empower providers to provide patient-centered contraception counseling to patients with a variety of health conditions and contraceptive preferences.
- |||||||||| Phexxi (citric acid/lactic acid/potassium bitartrate) / Evofem Biosci
Trial completion date, Trial primary completion date: Exploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal Microbiome (clinicaltrials.gov) - Sep 27, 2024
P1, N=22, Recruiting,
Updated evidence-based guidelines and several new contraceptive options should empower providers to provide patient-centered contraception counseling to patients with a variety of health conditions and contraceptive preferences. Trial completion date: Jun 2023 --> Dec 2025 | Trial primary completion date: Jun 2023 --> Oct 2025
- |||||||||| Phexxi (citric acid/lactic acid/potassium bitartrate) / Evofem Biosci
PREGNANCIES BY ACTS OF INTERCOURSE WITH VAGINAL PH MODULATOR: RESULTS FROM THE AMPOWER STUDY (Anaheim Convention Center - 207C) - Aug 21, 2022 - Abstract #ASRM2022ASRM_933;
P3
This post hoc analysis demonstrates that VPM users had a >99% chance of not getting pregnant at each act of intercourse. IMPACT STATEMENT: When providing counseling to women, these findings may serve as an additional tool to describe the efficacy of VPM to complement the Kaplan-Meier assessment.
- |||||||||| Twirla (ethinyl estradiol/levonorgestrel) / Agile Therap, Corium, Phexxi (citric acid/lactic acid/potassium bitartrate) / Evofem Biosci
Journal: New Contraception Update - Annovera, Phexxi, Slynd, and Twirla. (Pubmed Central) - Jul 8, 2022
Lastly, Twirla is a transdermal patch releasing ethinyl estradiol and levonorgestrel that offers users an additional option for a user-controlled, combined hormonal contraceptive method without daily dosing; however, prescription is limited to patients with BMI < 30 kg/m due to decreased efficacy and VTE events in people with obesity. The addition of these products expands the available options for pregnancy prevention to address unmet contraceptive needs.
- |||||||||| Phexxi (citric acid/lactic acid/potassium bitartrate) / Evofem Biosci
Characterization of Women Who Experienced Urinary Tract Infections in the Phase 3 AMPOWER Trial (Hall E) - Mar 31, 2022 - Abstract #ACOG2022ACOG_351;
P3
INTRODUCTION: Vaginal pH modulator (VPM; Phexxi) is a non-hormonal, on-demand, woman-controlled gel for the prevention of pregnancy... Compared to the overall AMPOWER population, women who experienced on-study UTIs had similar baseline characteristics and slightly lower product use.
- |||||||||| Phexxi (citric acid/lactic acid/potassium bitartrate) / Evofem Biosci
Trial completion, Trial completion date: Phase 2B/3 Double-blinded Placebo-controlled (clinicaltrials.gov) - Nov 21, 2019
P2b, N=860, Completed,
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial completion date: Feb 2020 --> Aug 2019
- |||||||||| Phexxi (citric acid/lactic acid/potassium bitartrate) / Evofem Biosci
Enrollment closed, Trial completion date, Trial primary completion date: Phase 2B/3 Double-blinded Placebo-controlled (clinicaltrials.gov) - Aug 14, 2019
P2b, N=844, Active, not recruiting,
Active, not recruiting --> Completed | Trial completion date: Feb 2020 --> Aug 2019 Recruiting --> Active, not recruiting | Trial completion date: May 2019 --> Feb 2020 | Trial primary completion date: Feb 2019 --> Sep 2019
- |||||||||| Phexxi (citric acid/lactic acid/potassium bitartrate) / Evofem Biosci
Trial completion: AMP002 Phase III Contraceptive Study (clinicaltrials.gov) - Aug 14, 2019
P3, N=1400, Completed,
Recruiting --> Active, not recruiting | Trial completion date: May 2019 --> Feb 2020 | Trial primary completion date: Feb 2019 --> Sep 2019 Active, not recruiting --> Completed
- |||||||||| Phexxi (citric acid/lactic acid/potassium bitartrate) / Evofem Biosci
Enrollment closed: AMP002 Phase III Contraceptive Study (clinicaltrials.gov) - Mar 7, 2018
P3, N=1400, Active, not recruiting,
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Phexxi (citric acid/lactic acid/potassium bitartrate) / Evofem Biosci
Enrollment open: Phase 2B/3 Double-blinded Placebo-controlled (clinicaltrials.gov) - Nov 17, 2017
P2b, N=844, Recruiting,
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||||||| Phexxi (citric acid/lactic acid/potassium bitartrate) / Evofem Biosci
Enrollment change: Phase 2B/3 Double-blinded Placebo-controlled (clinicaltrials.gov) - Oct 25, 2017
P2b, N=844, Not yet recruiting,
Not yet recruiting --> Recruiting N=634 --> 844
- |||||||||| Phexxi (citric acid/lactic acid/potassium bitartrate) / Evofem Biosci
New P3 trial: AMP002 Phase III Contraceptive Study (clinicaltrials.gov) - Aug 9, 2017
P3, N=1350, Recruiting,
- |||||||||| Phexxi (citric acid/lactic acid/potassium bitartrate) / Evofem Biosci
Trial initiation date: Phase 2B/3 Double-blinded Placebo-controlled (clinicaltrials.gov) - Jul 2, 2017
P2b, N=634, Not yet recruiting,
N=634 --> 844 Initiation date: May 2017 --> Oct 2017
|
